Wyeth stock down after several setbacks

Wyeth shares are reeling on the news that bifeprunox won't be approved. The stock is down about 7.5 percent since the FDA's "not approvable" letter was announced.

Coming on the heels of regulatory rejection of Pristiq, an antidepressant that was being tested for treatment of menopausal symptoms, and almost coincident with the halting of trials on Wyeth's hepatitis C hopeful (under development with ViroPharma), the bifeprunox blow was severe. Does Wyeth have enough new ideas up its pipeline to help pick up the slack? Some analysts think not; they're predicting a decline in sales and profits in 2010 or 2011 as blockbusters Effexor and Protonix come off patent. "The roof is leaking," says one. Unfortunately, fixing these kinds of holes isn't as easy as replacing a few shingles.

- read the article from The Wall Street Journal (sub. req.)
- and here's the report from Forbes

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.